Filing Flows › Entrada Therapeutics (TRDA) › Recalls, complaints & regulation
Entrada Therapeutics (TRDA): clinical trials
Entrada Therapeutics (TRDA) beyond its filings: 3 active clinical trials.
Entrada Therapeutics' latest quarter
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Entrada Therapeutics have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.